A B7-H3 Antibody Drug Conjugate Just Won a Second Phase 3, in a Second Tumour
A second positive Phase 3 in a second tumour makes Ris-Rez the only B7-H3 antibody-drug conjugate with late-stage wins across more than one cancer.
China Outbound
China Approved the World’s First Once-Daily Oral Factor B Inhibitor, and a US Small-Cap Licensed It a Month Early
China approved Haisco’s ciprocopan for PNH, the world’s first once-daily oral complement Factor B inhibitor, a month after a US small-cap licensed ex-China rights.
A Twice-Yearly Injection Cut Clotting Factor XI by 92%, With No Major Bleeding
A twice-yearly injection cut clotting Factor XI activity by 92% in coronary artery disease patients, with no major bleeding events in the Phase 2a study.